Venture Capital

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Dialed Moods' new sea moss and shilajit gummies enter a booming market. But do the ancient ingredients and modern science justify the industry's latest rush?

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Nusano won a "Best Company" award, but the real story is how its culture is a strategic asset powering its mission to disrupt the critical isotope market.

A funding round reveals a deeper strategy to tackle the healthcare labor crisis and soaring Medicaid costs with tech, data, and a focus on human dignity.

GWI's new AI award signals a major shift. Discover how AI is reshaping the water sector and which companies are poised to lead this tech-driven transformation.

Pacsun's new resale platform isn't just about old clothes. It's a strategic bet on curation, authenticity, and the circular economy to capture Gen Z.

A new Philadelphia lifestyle show is more than just real estate. It's a look at a disruptive media model using tech to turn local experts into TV stars.

A startup's breakthrough in GPS-denied warfare is redefining naval strategy and opening a new, complex frontier for strategic high-tech investment.

CPP Investments & General Atlantic's major stake in Boats Group signals a tech-driven shift in the marine market. Here's what it means for investors.

At the Asian Youth Para Games, advanced robots are not just performers; they are assistants, companions, and a glimpse into a more accessible future.

Subsense just raised $27M for a BCI delivered via nasal spray. It could democratize neurotech, but what's the cost to our identity and safety?

A new pediatric network is betting it can fix fragmented care with integrated tech and a focus on clinicians. Its latest target: Atlanta's crowded market.

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

A startup's legal victory protects its revolutionary wound care tech derived from the axolotl, paving the way for a new era in regenerative medicine.

The clean energy unicorn is betting on an NBA champ and a media acquisition to scale, signaling a major shift in how the industry wins over America.

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?